Jazz Pharmaceuticals Surges on Cancer Drug Trial Success
Update: 2025-11-17
Description
Jazz Pharmaceuticals shares surged over eighteen percent following positive results from a key clinical trial for its cancer drug, Ziihera. The HERIZON-GEA-zero-one trial showed that Ziihera, when combined with chemotherapy, significantly improved patient survival rates. Even more promising, when used with chemotherapy and tislelizumab, it showed meaningful improvement in overall survival rates, potentially becoming a new standard of care. This positive news stood out against a broader market trend, with investors moving away from tech and towards healthcare companies, showing strong confidence in Jazz Pharmaceuticals future.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
